Avalo Therapeutics (AVTX) News Today $5.04 0.00 (0.00%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$5.22 +0.19 (+3.67%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Allostery Investments LP Buys Shares of 73,314 Avalo Therapeutics, Inc. (NASDAQ:AVTX)Allostery Investments LP purchased a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 73,314 shares of the company's stock, valued at approximatelyMay 4 at 7:45 AM | marketbeat.comGeode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)Geode Capital Management LLC increased its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 937.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,853 shares of the comMay 4 at 3:13 AM | marketbeat.comAvalo Therapeutics to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC grew its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 1,123.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 550,765 shares of the company's stock after purchaApril 17, 2025 | marketbeat.comSeven new option listings and one option delisting on April 16thApril 17, 2025 | markets.businessinsider.comAvalo Therapeutics Reports 2024 Financial ResultsApril 16, 2025 | tipranks.comAvalo Therapeutics (AVTX) to Release Earnings on FridayAvalo Therapeutics (NASDAQ:AVTX) will be releasing earnings before the market opens on Friday, April 4, Financial Modeling Prep reports.March 28, 2025 | marketbeat.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by AnalystsShares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned aMarch 26, 2025 | marketbeat.comAvalo Therapeutics initiated with a Buy at JefferiesMarch 26, 2025 | markets.businessinsider.comAvalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel NicolausStifel Nicolaus started coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a "buy" rating and a $36.00 target price for the company.March 26, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Jefferies Financial GroupJefferies Financial Group began coverage on shares of Avalo Therapeutics in a research report on Tuesday. They set a "buy" rating and a $23.00 price objective for the company.March 26, 2025 | marketbeat.comAvalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardMarch 26, 2025 | globenewswire.comStifel initiates Avalo Therapeutics stock with a Buy ratingMarch 26, 2025 | investing.comStifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationMarch 25, 2025 | msn.comWedbush Research Analysts Lift Earnings Estimates for AVTXAvalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Equities researchers at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a report released on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.March 24, 2025 | marketbeat.comEquities Analysts Set Expectations for AVTX Q1 EarningsAvalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Avalo Therapeutics in a note issued to investors on Thursday, March 20th. HC Wainwright analyst E. White expects that the company will post earnMarch 24, 2025 | marketbeat.comQ1 EPS Estimates for Avalo Therapeutics Lifted by WedbushAvalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Wedbush increased their Q1 2025 earnings per share estimates for Avalo Therapeutics in a research report issued on Thursday, March 20th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $0.63 for the quMarch 22, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Avalo Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Given Outperform Rating at WedbushWedbush reiterated an "outperform" rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday.March 21, 2025 | marketbeat.comAvalo Therapeutics: Avalo Reports 2024 Financial Results and Recent Business UpdatesMarch 20, 2025 | finanznachrichten.deAvalo Reports 2024 Financial Results and Recent Business UpdatesMarch 20, 2025 | globenewswire.comAvalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on ThursdayAvalo Therapeutics (NASDAQ:AVTX) will be releasing earnings on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Growth in Short InterestAvalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 90,600 shares, an increase of 19.2% from the February 13th total of 76,000 shares. Currently, 1.1% of the company's shares are sold short. Based on an average daily trading volume, of 102,400 shares, the short-interest ratio is currently 0.9 days.March 19, 2025 | marketbeat.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest UpdateAvalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 76,000 shares, a growth of 75.5% from the January 31st total of 43,300 shares. Based on an average daily trading volume, of 88,800 shares, the short-interest ratio is presently 0.9 days. Approximately 0.9% of the company's shares are sold short.March 2, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper SandlerPiper Sandler started coverage on Avalo Therapeutics in a research report on Friday. They issued an "overweight" rating and a $48.00 price target on the stock.March 1, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight RecommendationMarch 1, 2025 | msn.comAvalo Therapeutics initiated with an Overweight at Piper SandlerFebruary 28, 2025 | markets.businessinsider.comPiper Sandler bullish on Avalo Therapeutics, initiates with an OverweightFebruary 28, 2025 | markets.businessinsider.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comAvalo Therapeutics (NASDAQ:AVTX) Upgraded at WedbushWedbush upgraded Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday.February 23, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Earns Outperform Rating from Analysts at WedbushWedbush began coverage on shares of Avalo Therapeutics in a research note on Friday. They set an "outperform" rating and a $18.00 price target on the stock.February 22, 2025 | marketbeat.comAvalo climbs as Wedbush issues bullish view on lead assetFebruary 21, 2025 | msn.comAvalo Therapeutics initiated with an Outperform at WedbushFebruary 21, 2025 | markets.businessinsider.comAvalo Therapeutics (NASDAQ:AVTX) Trading Up 3.1% - Time to Buy?Avalo Therapeutics (NASDAQ:AVTX) Trading Up 3.1% - Time to Buy?February 21, 2025 | marketbeat.comAvalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | finance.yahoo.comAvalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comShort Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8%Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 20,200 shares, a drop of 11.8% from the December 15th total of 22,900 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 84,800 shares, the days-to-cover ratio is currently 0.2 days.January 17, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% - Still a Buy?Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% - Here's WhyJanuary 17, 2025 | marketbeat.comAvalo Therapeutics Appoints Jennifer Riley As Chief Strategy Officer, Stock DownJanuary 2, 2025 | markets.businessinsider.comAvalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerJanuary 2, 2025 | globenewswire.comAvalo Therapeutics (AVTX) Has a New Rating from BTIGDecember 30, 2024 | markets.businessinsider.comShort Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Increases By 340.4%Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 22,900 shares, a growth of 340.4% from the November 30th total of 5,200 shares. Currently, 0.3% of the company's shares are sold short. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is presently 0.3 days.December 26, 2024 | marketbeat.comAvalo Therapeutics initiated with a Buy at BTIGDecember 21, 2024 | markets.businessinsider.comBTIG Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationDecember 21, 2024 | msn.comBTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)BTIG Research initiated coverage on Avalo Therapeutics in a research report on Thursday. They set a "buy" rating and a $40.00 price target for the company.December 19, 2024 | marketbeat.comLUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationDecember 18, 2024 | msn.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Drop in Short InterestAvalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,200 shares, a decrease of 46.9% from the November 15th total of 9,800 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 45,100 shares, the short-interest ratio is currently 0.1 days.December 12, 2024 | marketbeat.comRA Capital Management L.P. Invests $9.19 Million in Avalo Therapeutics, Inc. (NASDAQ:AVTX)RA Capital Management L.P. purchased a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 967,000 shares of the company's stock, valued at approximately $9,186,000. RADecember 5, 2024 | marketbeat.comAvalo Therapeutics receives $69.4M in proceeds from exercise of warrantsNovember 12, 2024 | markets.businessinsider.comAvalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNovember 12, 2024 | globenewswire.com Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Media Mentions By Week AVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTX News Sentiment▼1.020.73▲Average Medical News Sentiment AVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTX Articles This Week▼31▲AVTX Articles Average Week Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cardiff Oncology News Today Inventiva News Today Fulcrum Therapeutics News Today biote News Today SOPHiA GENETICS News Today Gossamer Bio News Today Annexon News Today TuHURA Biosciences News Today DBV Technologies News Today Prime Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTX Stock Free AVTX Stock Alerts